AdvanCell, a clinical-stage radiopharmaceutical company developing innovative cancer therapeutics, today announced the successful completion of an oversubscribed US$112 million Series C financing.
We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...
On February 10, the company announced a collaboration with AdvanCell to advance cancer treatment through targeted alpha therapies. By combining Eli Lilly and Company’s (NYSE:LLY) expertise in ...
The companies Eikon Therapeutics, Sionna Therapeutics, and Abcuro bagged the biggest biotech funding rounds overall in ...
AdvanCell has raised an oversubscribed US$112 million ($178.6 million) Series C round, enticing investors with its plan to produce cutting-edge nuclear medicines and novel cancer treatments.
The company also represents Advancell expandable microspheres, and S-LEC BK polyvinyl acetal resins. Sekisui Specialty Chemicals is a subsidiary of the Sekisui Chemical Group, a multibillion dollar, ...
Eli Lilly inks duo of deals, teaming with AdvanCell, OliX to push deeper into radiopharma, MASH FXRs, short for farnesoid X receptors, are nuclear receptors mainly expressed in the liver and ...
The company also represents Advancell expandable microspheres, and S-LEC BK polyvinyl acetal resins. Sekisui Specialty Chemicals is a subsidiary of the Sekisui Chemical Group, a multibillion ...